Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial

[1]  J. Boughey,et al.  Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach? , 2022, Current Breast Cancer Reports.

[2]  S. Hoover,et al.  Surgical Management of Axilla of Triple-Negative Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database , 2022, Annals of Surgical Oncology.

[3]  Jonathan M. Hernandez,et al.  Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy? , 2021, Annals of Surgical Oncology.

[4]  S. Hoover,et al.  Surgical Management of the Axilla of HER2+ Breast Cancer in the Z1071 Era: A Propensity-Score-Matched Analysis of the NCDB , 2021, Annals of Surgical Oncology.

[5]  John W. Davis,et al.  Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer , 2020, Annals of Surgical Oncology.

[6]  D. Berry,et al.  Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. , 2020, JAMA oncology.

[7]  A. Giuliano,et al.  Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis , 2019, Annals of Surgical Oncology.

[8]  R. Rouzier,et al.  Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study , 2018, Breast Cancer Research and Treatment.

[9]  L. Esserman,et al.  Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint , 2018, npj Breast Cancer.

[10]  A. Degnim,et al.  Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2018, Annals of Surgical Oncology.

[11]  G. Plitas,et al.  How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study , 2016, Annals of Surgical Oncology.

[12]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[14]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[15]  R. Carlos,et al.  Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. , 2009, Academic radiology.

[16]  J. Maublant,et al.  Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation , 2008, Annals of Surgical Oncology.

[17]  H. Kuerer,et al.  Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer , 2006, The British journal of surgery.

[18]  Mark C Kelley,et al.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer. , 2004, American journal of surgery.

[19]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.